You are right when it comes to their attack on the phase 3 based on lack of a randomised control group, but they also attack the use of a 45% overall response rate as the historical control which they say is too low. We have no way of knowing how weighty this criticism is. I expect MSB has the internal/proprietary data needed to back up its figure. They have done much more work in children's aGvHD than anyone else and they have the data to show for it. I don't believe they would have come this far without having this squared away. But even if it is on the low side, I think rem'l will still be viewed as an effective & side effects free treatment. If we get a unanimous or majority vote from AdCom then I think an approval for Covid19/ARDS is also pretty much in the bag.
- Forums
- ASX - By Stock
- Ann: FDA Advisory Committee Sets Review Date for Remestemcel-L
You are right when it comes to their attack on the phase 3 based...
-
- There are more pages in this discussion • 458 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.06 |
Change
0.030(2.91%) |
Mkt cap ! $1.210B |
Open | High | Low | Value | Volume |
$1.05 | $1.09 | $1.03 | $5.796M | 5.430M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 15990 | $1.06 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.08 | 48632 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 15990 | 1.060 |
3 | 33766 | 1.055 |
2 | 38526 | 1.050 |
4 | 79050 | 1.045 |
3 | 54455 | 1.040 |
Price($) | Vol. | No. |
---|---|---|
1.075 | 48632 | 3 |
1.080 | 108135 | 6 |
1.085 | 103276 | 9 |
1.090 | 239204 | 9 |
1.095 | 74283 | 8 |
Last trade - 16.10pm 02/09/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |